Skip to content

Released Nov 13, 2023, before the open

10-Q filed Nov 13, 2023, 44 days after period end · 0001576885-23-000062

Q3 2023 · 10-Q
Revenue—
Net Income-$12.96MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.24N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$16,039,000N/M
Operating Cash Flowderived-$12,905,000N/M
Free Cash Flowderived-$12,912,000N/M

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Net Income-$12.96M-$10.71M-$3.90M-$2.49M
EPS Diluted-$0.24-$0.26-$0.10-$5.94

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR